January 25, 2021

Calyx Launches CRO Partnership Program

ACTIVATE Partnership Program drives customer value for participating CROs

Nottingham, UK – Jan. 25, 2021 — Calyx, the eClinical solutions and services provider most relied on for solving complex data challenges in clinical research, today announced a valuable new partnership program for Clinical Research Organizations (CROs).

Calyx Chief Commercial Officer, John Blakeley, outlines how CROs can accelerate study execution, increase efficiencies, and improve study quality through Calyx’s partnership program.

The program, “ACTIVATE Solutions for CRO Partners,” is designed to provide close alignment between Calyx and its CRO partners. By participating in the ACTIVATE program, CROs can meet the needs of their many different clients and help accelerate trial execution and data collection, ultimately delivering more customer value.

“When designing the ACTIVATE partnership program, we listened closely to our CRO customers to identify the program elements that would be most beneficial,” said John Blakeley, Calyx Chief Commercial Officer. “We’re pleased to offer this valuable program that optimizes the important services our CRO partners provide to advance the global biopharmaceutical industry’s clinical development pipelines.”

Visit calyx.ai/CRO-partners for more information.

About Calyx

Through innovative eClinical solutions and services, Calyx turns the uncertain into the reliable, helping bring new medical treatments to market faster. With deep expertise in clinical development and more than 25 years of supporting trial sponsors and clinical research organizations (CROs), Calyx harnesses that intelligence and activates its potential to solve complex problems, deliver fast insights, and get new drugs to market every day.

Medical Imaging | IRT | CTMS | EDC | RIM

Take your trials further, faster at calyx.ai, LinkedIn, Twitter, or Facebook.

Media Contact:

Christine Tobin | Christine.Tobin@calyx.ai |+1 412-628-8598

Stay Updated

Never miss a beat. Sign up to receive emails covering industry news and useful content to help you advance clinical development.

  • This field is for validation purposes and should be left unchanged.